Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 5:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 369 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Metastatic Triple-Negative Breast Carcinoma Clear all
Recruiting Phase 1Phase 2 Interventional

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

NCT05579366
View directory record Official record
Conditions
High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC), Mesothelioma, Breast Adenocarcinoma, Triple Negative Breast Cancer, Hormone Receptor-positive/Her2 Negative Breast Cancer, Platinum-resistant Ovarian Cancer (PROC), Platinum Sensitive Ovarian Cancer (PSOC), Primary Refractory Ovarian Cancer, Uterine Cancer
Interventions
Rina-S, Carboplatin, Bevacizumab, Pembrolizumab
Drug
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
884 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
37
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 29, 2026, 5:36 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Homologous Recombination Repair Status as a Biomarker of Response in Locally Recurrent/Metastatic Triple Negative Breast Cancer Patients Treated With Concurrent Cisplatin and Radiation Therapy

NCT02422498
View directory record Official record
Conditions
Locally Recurrent/Metastatic Triple Negative Breast Cancer
Interventions
external beam radiation therapy, cisplatin, Biopsy of Target Tumor
Radiation · Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Sep 29, 2026, 5:36 AM EDT
Completed Phase 2 Interventional Results available

Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis

NCT03483012
View directory record Official record
Conditions
Breast Cancer
Interventions
Atezolizumab, Stereotactic radiosurgery (SRS)
Drug · Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 29, 2026, 5:36 AM EDT
Completed Phase 2 Interventional Results available

Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer

NCT00479674
View directory record Official record
Conditions
Breast Cancer
Interventions
Abraxane, Bevacizumab, Carboplatin
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
4
States / cities
Charlotte, North Carolina • Concord, North Carolina • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2015 · Synced Sep 29, 2026, 5:36 AM EDT
Recruiting Phase 1Phase 2 Interventional

PRE-ISPY Phase I/II Oncology Platform Program

NCT05868226
View directory record Official record
Conditions
HER2-positive Breast Cancer, Metastatic Cancer, Metastatic Breast Cancer, Metastatic, HER2-positive Metastatic Breast Cancer, HER2 Mutation-Related Tumors, HER-2 Protein Overexpression, HER2-negative Breast Cancer, Triple Negative Breast Cancer, HR Positive, Hormone Receptor-positive Breast Cancer, Estrogen Receptor Positive Tumor, Progesterone Receptor-positive Breast Cancer, Hormone Receptor Negative Breast Carcinoma, Solid Tumor, Solid Tumor, Adult, Solid Carcinoma, HER2 Low Breast Cancer, HER2 Low Breast Carcinoma, ER Positive Breast Cancer, PR-positive Breast Cancer, Minimal Residual Disease, Colo-rectal Cancer, Colon Cancer, Rectal Cancer, ctDNA Monitoring, Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms, Neoplasm, Residual, Adenocarcinoma of Colon, Adenocarcinoma
Interventions
ALX148, Fam-Trastuzumab Deruxtecan-Nxki, Zanidatamab, Tucatinib, TTX-MC138
Drug
Lead sponsor
QuantumLeap Healthcare Collaborative
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
10
States / cities
Birmingham, Alabama • Phoenix, Arizona • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 29, 2026, 5:36 AM EDT
Completed Phase 1 Interventional

Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer

NCT04134884
View directory record Official record
Conditions
Metastatic Breast Cancer, Triple Negative Breast Cancer, Hormone Receptor Positive Tumor
Interventions
Talazoparib, ASTX727
Drug
Lead sponsor
Kathy Miller
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Indianapolis, Indiana • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 21, 2024 · Synced Sep 29, 2026, 5:36 AM EDT
Withdrawn Phase 2 Interventional

Ixabepilone and SBRT For Metastatic Breast Cancer

NCT01818999
View directory record Official record
Conditions
METASTATIC BREAST CANCER
Interventions
IXABEPILONE, STEREOTACTIC BODY RADIATION THERAPY
Drug · Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 99 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2020 · Synced Sep 29, 2026, 5:36 AM EDT
Completed Phase 1Phase 2 Interventional

A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors

NCT04592484
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
CDK-002
Biological
Lead sponsor
Codiak BioSciences
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
4
States / cities
Scottsdale, Arizona • New York, New York • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2023 · Synced Sep 29, 2026, 5:36 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread

NCT03098550
View directory record Official record
Conditions
Advanced Cancer
Interventions
Nivolumab, Daratumumab
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
5
States / cities
Long Beach, California • Aurora, Colorado • Tampa, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2021 · Synced Sep 29, 2026, 5:36 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer

NCT02457910
View directory record Official record
Conditions
Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Negative, Progesterone Receptor Positive, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma
Interventions
Biomarker Analysis, Enzalutamide, Pharmacological Study, Taselisib
Other · Drug
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
12
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2022 · Synced Sep 29, 2026, 5:36 AM EDT
Recruiting Phase 1 Interventional

A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

NCT07503808
View directory record Official record
Conditions
Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer, Castration-resistant Prostate Cancer, Non Small Cell Lung Cancer, Endometrium Cancer, Triple Negative Breast Cancer
Interventions
IDE034
Drug
Lead sponsor
IDEAYA Biosciences
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
15
States / cities
Denver, Colorado • Sarasota, Florida • Detroit, Michigan + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 29, 2026, 5:36 AM EDT
Completed Phase 1 Interventional

A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors

NCT03849469
View directory record Official record
Conditions
Melanoma, Cervical Carcinoma, Pancreatic Carcinoma, Triple Negative Breast Cancer, Hepatocellular Carcinoma, Urothelial Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma, Renal Cell Carcinoma, Non-small Cell Lung Carcinoma, Small Cell Lung Carcinoma, Gastric or Gastroesophageal Junction Adenocarcinoma, Advanced or Metastatic Solid Tumors, Prostate Carcinoma, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Intrahepatic Cholangiocarcinoma, Squamous Cell Anal Cancer, Squamous Cell Penile Carcinoma, Squamous Cell Vulvar Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma
Interventions
XmAb®22841, Pembrolizumab (Keytruda®)
Biological
Lead sponsor
Xencor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
28
States / cities
Encinitas, California • La Jolla, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2023 · Synced Sep 29, 2026, 5:36 AM EDT
Recruiting Phase 1 Interventional

Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer

NCT05422794
View directory record Official record
Conditions
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Triple-Negative Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma
Interventions
BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Nab-paclitaxel, Pembrolizumab
Drug · Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
6
States / cities
Boston, Massachusetts • Mineola, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 29, 2026, 5:36 AM EDT
Recruiting Phase 2 Interventional

Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies

NCT07340541
View directory record Official record
Conditions
Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer, Estrogen-receptor-positive Breast Cancer, Hormone Receptor Negative Breast Carcinoma
Interventions
SERD* + abemaciclib, SERD* + everolimus, SERD* + everolimus or capecitabine, SOC, Antiandrogen
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
6
States / cities
New Haven, Connecticut • Baltimore, Maryland • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 29, 2026, 5:36 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca

NCT02041429
View directory record Official record
Conditions
Recurrent Breast Cancer, Metastatic Breast Cancer
Interventions
Ruxolitinib, Paclitaxel
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 20, 2021 · Synced Sep 29, 2026, 5:36 AM EDT
Completed Phase 1 Interventional

Dose Escalation of POL6326 in Combination With Eribulin in Patients With Metastatic Breast Cancer

NCT01837095
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
POL6326
Drug
Lead sponsor
Polyphor Ltd.
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
5
States / cities
Kansas City, Kansas • St Louis, Missouri • Lebanon, New Hampshire + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2018 · Synced Sep 29, 2026, 5:36 AM EDT
Completed Not applicable Interventional

Mobile Health to Improve Oral Chemotherapy Adherence Among Women With Breast Cancer

NCT05086731
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Localized Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma, Metastatic Breast Cancer
Interventions
Best Practice, Informational Intervention, Medical Device Usage and Evaluation, Quality-of-Life Assessment, Survey Administration
Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
4
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 16, 2025 · Synced Sep 29, 2026, 5:36 AM EDT
Completed Phase 2 Interventional Results available

Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer

NCT02648477
View directory record Official record
Conditions
Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Negative, Progesterone Receptor Positive, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma
Interventions
Anastrozole, Doxorubicin Hydrochloride, Exemestane, Laboratory Biomarker Analysis, Letrozole, Pembrolizumab
Drug · Other · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
6
States / cities
Corona, California • Duarte, California • Lancaster, California + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Sep 29, 2026, 5:36 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Re-expression of ER in Triple Negative Breast Cancers

NCT01194908
View directory record Official record
Conditions
Breast Cancer, Breast Tumors, Breast Neoplasms
Interventions
Decitabine, LBH589, Tamoxifen
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 25, 2015 · Synced Sep 29, 2026, 5:36 AM EDT
Recruiting Phase 2 Interventional

Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy

NCT05770531
View directory record Official record
Conditions
Metastatic HER2-Negative Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma
Interventions
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Sacituzumab Govitecan
Procedure · Biological
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Sep 29, 2026, 5:36 AM EDT
Completed Phase 2 Interventional

Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Previously Treated With Enzalutamide, Androgen Receptor Positive Triple-Negative Breast Cancer Patients, and Men With ER Positive Breast Cancer

NCT02130700
View directory record Official record
Conditions
Prostate Cancer
Interventions
VT-464: given orally twice daily in 28-day cycles, VT-464: given orally once daily in 28-day cycles
Drug
Lead sponsor
Innocrin Pharmaceutical
Industry
Eligibility
18 Years and older · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 6, 2018 · Synced Sep 29, 2026, 5:36 AM EDT
Completed Phase 1 Interventional

Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer

NCT02309177
View directory record Official record
Conditions
Breast Neoplasms, Pancreatic Neoplasms
Interventions
nab-Paclitaxel, Nivolumab, Gemcitabine, Carboplatin
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
15
States / cities
Sacramento, California • Santa Monica, California • New Haven, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated May 30, 2019 · Synced Sep 29, 2026, 5:36 AM EDT
Terminated Phase 1 Interventional

A Study to Investigate LYL797 in Adults With Solid Tumors

NCT05274451
View directory record Official record
Conditions
Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Non-small Cell Lung Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Non-Small Cell Carcinoma of Lung, TNM Stage 4, Advanced Breast Cancer, Advanced Lung Carcinoma, NSCLC, NSCLC, Recurrent, NSCLC Stage IV, Relapsed Cancer, Relapse/Recurrence, Recurrent Breast Cancer, Recurrent NSCLC, Platinum-resistant Ovarian Cancer, Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Endometrioid Tumor, High Grade Serous Carcinoma, Ovarian Epithelial Cancer
Interventions
LYL797
Biological
Lead sponsor
Lyell Immunopharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
18
States / cities
Scottsdale, Arizona • Santa Monica, California • New Haven, Connecticut + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2025 · Synced Sep 29, 2026, 5:36 AM EDT
Recruiting Phase 1 Interventional

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

NCT06465069
View directory record Official record
Conditions
Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Esophageal Cancer, Pancreatic Cancer, Ovarian Cancer, Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Prostate Cancer, Renal Pelvis Cancer, Bladder Cancer
Interventions
LY4052031
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
21
States / cities
Duarte, California • La Jolla, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 29, 2026, 5:36 AM EDT